Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acrivon Therapeutics, Inc. (ACRV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Acrivon is a clinical stage biopharmaceutical company focused on precision oncology medicines developed using its Generative Phosphoproteomics AP3 platform, and its filings offer additional context on financial results, clinical programs, and business updates.
Among the documents available for ACRV are current reports on Form 8-K, which Acrivon uses to furnish press releases announcing quarterly financial results and to provide Regulation FD disclosures. For example, the company has filed 8-K reports to attach earnings press releases summarizing research and development expenses, cash and investment balances, and narrative business highlights, as well as to furnish a corporate presentation describing AP3 capabilities, synergy data for ACR-368 and ACR-2316 with immune checkpoint inhibitors, and updates to its pipeline overview.
Through this page, users can track how Acrivon reports its progress with lead programs such as ACR-368, a CHK1/CHK2 inhibitor in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, and ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, along with AP3-driven preclinical initiatives. Real-time updates from EDGAR ensure that new ACRV filings, including additional 8-Ks and other periodic reports, are reflected as they become available.
Stock Titan’s interface is designed to pair these filings with AI-powered summaries that explain the key points of each document in clear language. Users can quickly see what each ACRV filing covers—such as financial condition, clinical data highlights, or platform developments—while retaining the ability to open the full SEC text for detailed review, including any exhibits like press releases or corporate presentations incorporated by reference.
Acrivon Therapeutics insider sale reported on Form 4. Katharine Peterson, Chief Accounting Officer, recorded a transaction dated 08/14/2025 disclosing a disposition of 99 shares of Acrivon Therapeutics common stock at a price of $1.39 per share. Following the reported sale, Ms. Peterson beneficially owns 4,221 shares, held directly. The filing states the 99 shares were withheld by the issuer to satisfy mandatory tax withholding upon RSU vesting and is signed by an attorney-in-fact on 08/18/2025.
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on 08/14/2025 involving the company’s common stock. The filing shows 184 shares were disposed at a price of $1.39 per share.
The form states these shares were withheld by the issuer to satisfy a mandatory tax withholding obligation upon the vesting of restricted stock units. After the withholding, Ms. Miller beneficially owns 35,581 shares directly. The Form 4 was signed by an attorney-in-fact on 08/18/2025.
Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, reported a routine withholding of 403 shares of Common Stock on 08/14/2025 to satisfy mandatory tax withholding when restricted stock units vested. The withheld shares were disposed at a reported price of $1.39 per share. After the transaction, Mr. Gamelin beneficially owns 15,686 shares of ACRV common stock. The Form 4 was signed by an attorney-in-fact on 08/18/2025. The filing notes the withholding was to cover taxes tied to RSU vesting.
Acrivon Therapeutics insider transaction summary: Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, reported a single Form 4 transaction. On 08/14/2025 the reporting person had 613 shares withheld at a price of $1.39 per share as a result of tax withholding tied to the vesting of restricted stock units. After this withholding disposition, the reporting person beneficially owns 65,921 shares of Acrivon common stock, held directly. The Form 4 was signed by an attorney-in-fact on 08/18/2025. The filing notes the withholding was to satisfy mandatory tax obligations and includes a Power of Attorney exhibit.
Acrivon Therapeutics insiders reported routine post-vesting share dispositions on 08/14/2025. The Form 4 shows that restricted stock units were treated by the issuer to cover mandatory tax withholding: 59,766 shares were withheld at an effective price of $1.39, recorded as a disposition. After that transaction, Peter Blume-Jensen is shown as beneficially owning 2,146,345 shares (direct) and 315,196 shares (indirect) attributable to spouse holdings. A separate small disposition of 490 shares at $1.39 is reported as indirect ownership. Both Dr. Blume-Jensen (President and CEO) and Dr. Kristina Masson (EVP, Business Operations) are listed as reporting persons and each signed via attorney-in-fact on 08/18/2025.
Acrivon Therapeutics (ACRV) presented interim financials and clinical progress through June 30, 2025. The company recorded a six-month net loss of $40.7 million, bringing an accumulated deficit to $237.7 million, and reported cash, cash equivalents and investments of $147.6 million, which management says funds operations into the second quarter of 2027. Acrivon remains pre-revenue and continues to invest heavily in R&D.
Clinically, ACR-368 is in a registrational-intent Phase 2 program for endometrial cancer using the proprietary OncoSignature biomarker; an interim cohort of OncoSignature-positive patients showed a 35% confirmed overall response rate and tumor shrinkage in 80% of patients. ACR-2316 is in Phase 1 with early target engagement and a confirmed partial response observed at Dose Level 3. The company retains licensed rights to prexasertib under a Lilly agreement with up to $168 million in milestone payments and tiered royalties up to 10%.
This Schedule 13G/A reports that Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands jointly beneficially own 2,122,605 shares of Acrivon Therapeutics common stock, representing 6.8% of the outstanding shares based on 31,355,361 shares reported by the issuer. The filing shows no sole voting or dispositive power and indicates shared voting and dispositive power over the reported shares, consistent with a passive investor position.
The filing names the reporting entities, identifies their places of organization (Cayman Islands, Delaware and United States), provides the issuer's principal office address, and includes a certification that the securities were not acquired to change or influence control of the issuer.